THE BUILDERS / COMPANY RESEARCH
Merck
Develops medicines; co-develops intismeran with Moderna. Company trial reports are not approvals.
Revenue history & outlook
Consolidated annual company revenue; all business lines, not AI-only sales. · USD billion
| Period | Revenue | Classification | Published | Source |
|---|---|---|---|---|
| FY2021 · ended Dec 31, 2021 | ≈48.7 | Reported observation | 2026-09-04 | Stock Analysis / S&P Global |
| FY2022 · ended Dec 31, 2022 | ≈59.28 | Reported observation | 2026-09-04 | Stock Analysis / S&P Global |
| FY2023 · ended Dec 31, 2023 | ≈60.12 | Reported observation | 2026-09-04 | Stock Analysis / S&P Global |
| FY2024 · ended Dec 31, 2024 | ≈64.17 | Reported observation | 2026-09-04 | Stock Analysis / S&P Global |
| FY2025 · ended Dec 31, 2025 | ≈65.01 | Reported observation | 2026-09-04 | Stock Analysis / S&P Global |
| FY2026 · analyst consensus | ≈67.14 | Independent projection | 2026-09-04 | Stock Analysis / S&P Global |
| FY2027 · analyst consensus | ≈70.3 | Independent projection | 2026-09-04 | Stock Analysis / S&P Global |